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Abstract 
Purpose: To assess adherence to existing clinical practice standards regarding screening and 
monitoring of patients with monoclonal gammopathy of undetermined significance (MGUS) to 
detect progression to multiple myeloma. To accomplish this, this study will determine if having 
MGUS or a higher level of monoclonal protein (M-protein) significantly increases measures of 
health care utilization. 
Background: Current clinical standards recommend monitoring MGUS patients with annual 
serum protein electrophoresis (SPEP) to detect changes in M -protein level. It is important to 
assess whether MGUS patients seek sufficient care and are adequately followed, because a 
significant portion of MGUS cases can progress to more clinically significant plasma cell 
disorders such as multiple myeloma. 
Patients and Methods: Subjects were from the Duke Established Populations for the 
Epidemiologic Study of the Elderly, a random sampling of community residents. Subjects were 
interviewed annually from 1986-1992 and once in 1996 to assess a broad range of social and 
health conditions, including health utilization patterns. Subjects aged 70 or older (n=1730), 
t--
consented to a blood draw in 1992. SPEP and immunofixation were used to determine 
monoclonal immunoglobulins, and 106 subjects were diagnosed with MGUS. In 1996, subjects 
were asked about their health care utilization practices, including number of hospitalizations, 
outpatient medical visits, emergency room (ER) visits, and nursing home (NH) admissions in the 
past year. Student's t-test analysis for continuous variables and Fisher exact test for categorical 
variables were used to compare MGUS and non-MGUS subjects on several factors. Pearson's 
correlation between M-protein level and health care utilization outcomes was performed. Linear 
regression models were used to determine the independent effect of the presence of MGUS on 
health care utilization when controlled for demographics, habits, and comorbidities. To validate 
the MGUS subjects' responses and assess the completeness of follow-up care, a medical record 
chart review study was performed. 
Results: The number ofER visits was significantly lower (p=0.04) and the number ofNH 
admissions significantly higher (p=0.04) in subjects with MGUS compared to those without. 
The number of hospitalizations and outpatient visits were not significant! y different between 
MGUS subjects and controls. M-protein level was found to be correlated with the number ofER 
visits (r=0.48, p<O.OOOl) and hospitalizations (r=0.60, p=0.02), but not with the number of 
outpatient visits or NH admissions. Qualitative assessment of medical charts revealed sparse and 
incomplete medical follow-up of MGUS. 
Conclusion: It would be expected that, if adequately followed, MGUS patients should experience 
higher health care utilization compared to those without. We found that patients with MGUS 
had increased NH admissions and decreased ER visits but did not differ significantly in number 
of hospitalizations or outpatient visits, a better indicator of follow-up care for MGUS. M-protein 
level was associated with the number of ER visits and hospitalizations, but not NH admissions or 
outpatient visits. Combined with the inadequate follow-up seen in the medical records, these 
findings suggest a need to increase awareness among patients and physicians of existing 
guidelines for follow-up care of an MGUS patient and the significant potential for MGUS to 
develop into more clinically significant disease or malignancy. 
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Introduction 
In adults, multiple myeloma is the most common primary cancer of the bone, with an 
annual incidence of 4 per 100,000, and it accounts for 1% of all cancer-related deaths in the 
Western countries (1 ). Multiple myeloma is characterized by a malignant proliferation of plasma 
cells in the bone marrow that can lead to clinical manifestations that include anemia, bone 
destruction, renal failure, hypercalcemia, hyperviscosity, and recurrent infections. The myeloma 
plasma cells secrete homogeneous immunoglobulins that are detected in serum protein 
electrophoresis (SPEP) as a monoclonal protein (M-protein). 
The development of multiple myeloma is preceded by a much more common 
asymptomatic condition known as monoclonal ganunopathy of undetermined significance 
(MGUS). There are over 1 million cases of MGUS diagnosed in the United States per year (2). 
As in multiple myeloma, uncontrolled proliferation of plasma cells from a single clone occurs in 
MGUS, but clinical symptoms are absent and theM-protein level is lower. The diagnosis of 
MGUS is made through the detection of an M-protein, usually IgG or IgA, by SPEP. In MGUS, 
the monoclonal level of IgG is less than 3.5 g/dL and IgA is less than 2 g/dL, there are fewer 
than 10% plasma cells in the bone marrow, and there are no or minimal amounts of M -protein in 
the urine (less than 1 g/24h) (3). MGUS occurs in about 0.15% of the general population (4), 
and is concentrated mainly among the elderly. In a study of 7,000 subjects with MGUS in 
Malmo, Sweden, there was a prevalence of 2% in subjects aged 70-79 and a 5.7% prevalence in 
those over 80 (5). 
In the spectrum of plasma cell disorders, MGUS is the most benign and common 
condition. In the natural progression of MGUS, it most frequently continues in a benign 
asymptomatic state, but it can also develop into more clinically significant plasma cell disorders, 
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including smoldering multiple myeloma, systemic amyloidosis, Waldenstrom's disease, multiple 
myeloma, or other lymphoproliferative disorders. Most patients with MGUS eventually die of 
an unrelated disease, but clinically significant plasma cell disease does emerge in about 1.5% of 
MGUS patients each year (6). In their lifetime, about 20-30% of MGUS patients go on to 
develop a malignant process (3). In Kyle's study following 241 patients with MGUS for 20 to 
35 yrs at the Mayo Clinic, 24% of patients eventually developed multiple myeloma, systemic 
amyloidosis, macroglobulinemia, or a malignant lymphoproliferative disorder (7). The median 
age of diagnosis of MGUS was 64. The median time interval from detection of an M-protein to 
diagnosis of a clinically significant plasma cell disease ranged from 8 to 10.5 years. Other 
studies have shown a shorter median time to transformation (6-8 yrs) for multiple myeloma (3). 
In Pasqualetti's study, 263 subjects with MGUS received 5 to 20 years of follow-up, and 18.3% 
developed multiple myeloma or another lymphoproliferative disease in that time period (8). Of 
the patients in Kyle's study who developed a clinically significant plasma cell disorder, 68% 
specifically developed multiple myeloma, which translates to an annual risk of 0.8% (7). 
Significantly, MGUS can convert to malignancy years after initial detection, so patients should 
be informed of the risks and receive close follow-up. 
The initial level of monoclonal protein may predict the development of clinically 
significant plasma cell disease. Changes in theM-protein level are monitored in a patient with 
MGUS to watch for the development of multiple myeloma. In a cohort study of 1,384 patients, 
the level of M-protein at the time of diagnosis with MGUS was directly related to progression 
(9). The risk of progression to multiple myeloma or a related disorder 10 years after diagnosis of 
MGUS was 7% for those with an initial M-protein level of I g/dL or less, 20% for 2 g/dL, and 
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34% for 3 g/dL. Corresponding rates for progression were 16%,41%, and 64%, respectively, at 
20 years. 
It is important for a patient with MGUS to receive good follow-up care, because if 
multiple myeloma is discovered, treatment can be initiated to decrease morbidity and improve 
quality of life. For example, appropriate chemotherapy can be started or symptoms can be 
treated, such as giving erythropoietin for anemia or managing hypercalcemia (10). Currently, 
multiple myeloma is incurable, but earlier treatment can delay the development of severe clinical 
manifestations, such as lytic lesions and renal failure. 
Certain follow-up medical tests should be done with patients presenting with a new 
diagnosis of MGUS. In 1999, a panel of experts formed by the College of American 
Pathologists, in conjunction with the American Society of Hematology, the American College of 
Rheumatology, the Clinical Center of the National Institutes of Health, and the Clinical 
Immunology Society, established the first set of guidelines for laboratory diagnosis and 
monitoring of monoclonal garnmopathies. The recommendations describe the clinical conditions 
in which monoclonal protein should be sought, the optimal sequence of testing to diagnose and 
monitor these patients, and the most effective laboratory procedures (2,11). According to the 
guidelines, immunofixation should follow the initial high-resolution SPEP in order to define the 
type of abnormal protein. At minimum, an asymptomatic MGUS patient with a noncontributory 
history and physical exam and serum M-protein less than 1.5 g/dL should receive annual SPEPs. 
For an asymptomatic patient with M-protein of 1.5 to 2.5 g/dL, additional minimum studies 
should include nephelometry for quantitation of immunoglobulins and collection of a 24-hour 
urine specimen for electrophoresis and immunofixation. SPEP should be repeated in 3 to 6 
months, and if stable, it should be repeated annually or sooner if any symptoms or complications 
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are present. If theM-protein is greater than 2.5 g/dL, there is a higher likelihood of multiple 
myeloma, so a metastatic bone survey, including single views of the humeri and femurs, should 
be done. An aspirate and biopsy of the bone marrow should also be seriously considered. If 
these studies are negative, then SPEP should be repeated in 2 to 3 months, then again in 3 to 4 
months if stable, and then annually if still stable. 
From a public health perspective, it is important to assess whether patients who are 
diagnosed with MGUS seek sufficient care and are adequately followed medically. The purpose 
of this study is to assess adherence to existing clinical practice standards regarding screening and 
monitoring of patients with MGUS to detect progression to multiple myeloma. To accomplish 
this, the study looks at whether having MGUS is associated with significantly increased health 
care utilization, measured by hospitalizations, emergency room (ER) visits, nursing home (NH) I admissions, and outpatient visits. More specifically, this study also explores whether the 
presence of M -protein is correlated with the amount of health utilization. Health care utilization 
outcomes are controlled for age, gender, race, education, marital status, employment status, 
pack-year smoking, alcohol consumption, and comorbidities, because all of these confounding 
variables may affect a person's health care utilization (12). Additionally, available medical 
records were reviewed to validate subjects' health care utilization and assess the completeness of 
follow-up care for MGUS. It is hypothesized that, compared to subjects without MGUS, patients 
with MGUS should have significantly higher health care utilization due to existing clinical 
recommendations for increased monitoring and follow-up care. It is also hypothesized that, 
within the group of subjects with MGUS, higher levels of M-protein should correlate with 
increased health care utilization in concordance with the guidelines for care of a patient with 
monoclonal gammopathy. 
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Materials and Methods 
Subjects 
Subjects of this study originated from the Duke University Established Populations for 
the Epidemiologic Studies of the Elderly (EPESE) (14). The EPESE project was designed as a 
6-year (1986/87-1992/93) longitudinal study of community residents aged 65 years and older on 
whom information was obtained annually. EPESE began as a random sample of 28,000 persons 
over the age of 65 who live in five adjacent counties in the Piedmont region of North Carolina. 
It was structured to select approximately equal numbers of black and white participants. The 
annual evaluations were designed as in-home personal interview or telephone interview with a 
combination of self-reported, interviewer-tested and interviewer-observed information was 
collected. Additionally, a personal interview was performed in 1996. The evaluations assessed 
subjects' cognitive and functional status, depression, life satisfaction, social interactions, chronic 
health conditions, medications, and health utilization (13,14). 
All subjects in this study are aged 70 or older, which is the select age range of the 
population with highest prevalence of MGUS. Furthermore, there are a significant number of 
African Americans in the MGUS group, which is important because prevalence of MGUS 
among African Americans has been found to be significantly higher than among Caucasians. In 
a previous study involving our subjects, there was a prevalence of 8.4% in African Americans 
and a prevalence of 3.8% in Caucasians (15). 
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Main Outcome Variables 
The main outcome variables are number of outpatient visits, ER visits, hospitalizations, 
and nursing home admissions over the last 12 months preceding the interview in 1996. The year 
1992 was treated as the baseline year of diagnosis of MGUS, and endpoints were assessed using 
data from the 1996 interview. In 1996, living patients were asked about health utilization, 
including the number of times that they were seen in an outpatient setting, had visited an ER, 
were hospitalized overnight, and had been admitted to a nursing home within the past 12 months. 
The total number of hospitalizations, ER visits, NH admissions, and outpatient visits were 
compared between MGUS and non-MGUS subjects. These numbers were collected from the 
EPESE dataset as discrete counts, and the mean number of each variable was found for the 
MGUS group and the non-MGUS group. Dependent variables were measures of health care 
utilization, including number of outpatient visits, ER visits, hospitalizations, and nursing home 
admissions. These variables were also examined within the MGUS patients for association with 
initial M-protein leveL 
Main Exposure Variable 
MGUS and M-protein level. The independent variable was whether the subject had MGUS 
(n=l06 with MGUS, n= 1624 without MGUS). In 1992-1993, serum protein electrophoresis was 
conducted on 1,730 of the EPESE patients who consented to blood drawing, all of whom were 
over 70 years of age at the time. A total of 106 subjects were found to have abnormally elevated 
serum protein levels. The 106 subjects were made aware of their elevated protein level at the 
time of their bloodwork and given the option of having their primary care physician notified of 
the results. 
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Co variates 
Convariates measured included age, gender, race, education, marital status, employment 
status, pack-year smoking, alcohol consumption, and comorbidities found in the 1992 evaluation. 
Age, education, smoking, and alcohol consumption. These variables were coded into SAS as 
discrete numbers representing age, number of years of education (maximum=17), pack-years of 
smoking, and drinks per month for alcohol consumption. 
Gender, race, marital status, employment. These variables were coded into SAS as postive or 
L 
negative, with female gender, African American, married, and employed set as positives. 
Comorbidities. A total of sixteen comorbid conditions were analyzed. At the outset ofEPESE, 
subjects were asked at each annual interview whether they had experienced a myocardial 
infarction, stroke, hip fracture or fracture of another bone or were diagnosed with cancer, 
diabetes or hypertension during the past year. In 1992-1993, additional information regarding 
the presence of arthritis, osteoporosis, glaucoma, Parkinson's disease, anemia, lung disease, liver 
disease, depression, and cognitive impairment was collected. A total of 2,567 subjects 
participated in the in-home personal interview in 1992-1993. Subjects were coded as either 
positive or negative for having each of the comorbidities. 
Validation Study 
To validate subjects' responses to their health care utilization and follow-up care for 
MGUS, a medical chart review study was performed from October 2002 until April 2003. The 
106 subjects or, for deceased subjects, their power of attorney, were contacted to consent them 
for release of medical records from 1992 to present. 44 subjects consented, 12 subjects refused 
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to participate, 1 spoke Spanish only, and 49 failed to return consents after repeated requests or 
had outdated contact information and could not be reached. On the consent forms, patients were 
asked to list names of their primary care physicians, any hospitals where they have received 
treatment, and any names of nursing homes where they have stayed since 1992. 
Medical records were obtained for 37 patients, some of whom listed multiple sources of 
health care utilization (primary care physician and hospital). Some records for deceased patients 
could not be located. In total, 23 records were received from primary care physicians, 29 records 
were received from hospitals, and 2 records were received from nursing homes. A chart review 
was done on these medical records to examine whether there was any follow-up regarding the 
monoclonal protein diagnosis, medical care and tests appropriate for the diagnosis of MGUS, 
and number of hospitalizations, ER visits, NH admissions, and outpatient visits. All MGUS-
related studies (such as UPEP, nephelometry, bone scans, or bone marrow analysis) done from 
1992 to 1993 were included as baseline studies for initial workup ofMGUS. 1994 was defined 
as the first year of follow-up, 1995 as the second year, etc. 
Statistical Analysis 
In our study, we hypothesized that, compared to subjects without MGUS, patients with 
MGUS should have significantly higher health care utilization due to existing clinical 
recommendations for increased monitoring and follow-up care. We also hypothesized that, 
within the group of subjects with MGUS, higher levels of M-protein should correlate with 
increased health care utilization in concordance with the guidelines for care of a patient with 
monoclonal gammopathy. All data were analyzed using SAS version 8.1 (Cary, NC). 
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Univariate analysis of all independent and dependent variables and covariates was 
performed to describe the characteristics of the study population. Bivariate analyses were 
performed to assess for differences between the MGUS group and controls. Continuous 
variables (age, education, smoking, and alcohol consumption) were analyzed using Student's t-
test. Categorical variables (gender, race, marital status, employment, and comorbidities) were 
evaluated using contingency tables with Chi-square analysis utilizing Fisher exact test. 
Linear regression models were then constructed to determine the independent effect of 
MGUS diagnosis on each of the health care utilization indicators, controlling for the covariates. 
All the variables of age, gender, race, marital status, employment, education, smoking, alcohol 
consumption, and comorbidities were included and controlled as possible confounders, because 
these factors can influence health care utilization. 
Separately, within just the MGUS group, Pearson's correlation was used to test for linear 
association between level of M-protein and each of the outcome variables. M-protein level and 
the outcomes are continous variables, so Pearson's correlation was used. 
A two-sided p (<0.05level of significance) was used to determine whether to accept or 
recject the null hypothesis. A two-sided test was used instead of a one-sided test because results 
would be still have important implications if MGUS patients were found to have lower health 
care utilization than non-MGUS patients rather than the expected higher health care utilization. 
9 
Results 
The age of the 1,730 subjects ranged from 71 to 102 years with a mean age of 78. 
Women constituted 65% of the subjects, and 53% of subjects were African American. MGUS 
was found in 106 ( 6.1%) of the subjects. The serum globulin levels ranged from 0 to 4.4 g/dL, 
and the mean globulin level was 1.32 g/dL. TheM-protein levels ranged from 0.12 to 4.32 g/dL 
and the mean M-protein level was 0.94 g/dL. Figure 1 shows the distribution of M-protein levels 
among the subjects. 
Table 1 describes the characteristics of the MGUS and non-MGUS groups. The means 
(for continuous variables) or percentages (for categorical variables) for the MGUS and non-
MGUS group are listed along with the p-value. The MGUS group was older, mean age 79.1 
years, compared to the non-MGUS group, mean age 77.8 years (p=0.02). Compared to non-
MGUS subjects, MGUS subjects had a higher percentage of African Americans (p<0.0001) and 
males (p=0.04) and a lower incidence of osteoporosis (p=0.04). None of the other variables are 
significantly different between the MGUS and non-MGUS groups. 
Table 2 lists the results of the regression analysis of tbe association between the presence 
of MGUS and the health care utlilization outcomes. After controlling for confounding variables 
with linear regression, having MGUS was associated with a decreased number of ER visits 
(0R=0.76, p=0.04). The MGUS group had a mean of 0.3 visits (range 0-4) while the non-
MGUS group had a mean of 0.5 visits (range 0-15). Having MGUS increased the likelihood of 
NH admissions (OR=l.34, p=0.04). The MGUS group had a mean of 1.4 admissions (range 1-2) 
while the non-MGUS group had a mean of 1.1 admissions (range 1-3). There were no 
significant differences between the 2 groups in the number of overnight hospitalizations and 
outpatient visits. 
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Tab!~ 3lists the results of the correlation analysis between M-protein level and health 
care utlilization outcomes. There was no significant correlation found between M-protein level 
and number of outpatient visits (r=0.17, p=0.17) and nursing home admissions (r=0.37, p=0.42). 
However, the correlation between M-protein level and ER visits (r=0.48, p<0.0001) and 
hospitalizations (r=0.60, p=0.02) was significant. 
In the second portion of our study, the medical chart review, records were obtained for 37 
of the 106 subjects (34.9%). Of these, 23 were women (62.2%) and 23 were African-Americans 
(62.2%). In 1992, 15 ofthe 37 subjects (40.5%) had requested that results of the abnormal 
protein study be sent to their primary care physicians at the time. For all 15 subjects, the primary 
care physicians noted the MGUS finding in their medical charts. Serum immunoglobulin levels 
ranged from 0.31 to 4.18 g/dL, with a mean level of 1.245 g/dL. 
Follow-up studies at and after diagnosis of MGUS were inadequate for the majority of 
subjects. From 1992 to 2003, only 7 of the 37 subjects (19%) had medical records that included 
documentation of at least one repeat SPEP, and of those, 2 were diagnosed with multiple 
myeloma in 1993 (initial SPEPs in 1992 were 4.18 g/dL and 1.32 g/dL), and 1 developed 
multiple myeloma in 1999 (initial SPEP 1.25 g/dL). During the baseline years of 1992-1993, 
general labs including creatinine, calcium, hemoglobin, platelets, and white blood cell counts 
with differential were performed on 10 of the subjects (27%). UPEPs were noted in the charts of 
3 subjects (8.1 %), who had initial SPEPs of 1.32, 1.35, and 4.18 g/dL. Bone marrow biopsies 
were performed on 6 subjects (16.2%), with findings of 40%, 60%, 80% plasma cells (initial 
SPEPs respectively, 0.44 g/dL, 1.25 g/dL, 4.18 g/dL), 1 subject's bone marrow biopsy was noted 
as "without plasma cells" in the chart, and 2 subjects without bone marrow biopsy results in their 
charts. Radiologic skeletal surveys or bone scans were done in 5 subjects (13.5%) with initial 
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SPEPs of 4.18, 1.48, 1.32, 1.04, and 0.44 g/dL, all of which were negative for lytic lesions. One 
of those subjects had a history of prostate cancer (SPEP 1.48 g/dL). 
In the first year of follow-up (1994), 10 subjects had documentation of being seen in the 
medical community, either at a hospital, outpatient clinic, or ER. In 1995, 10 subjects were seen, 
one who had a bone metastasis from a previous colon cancer, had light chains found in a urine 
study, and had a negative bone survey (initial SPEP 1.45 g/dL). In the third year, 12 subjects L 
were seen, and 1 subject developed low grade B-ee!! follicular lymphoma (initial SPEP 0.86 
g/dL). In the fourth year, 9 subjects were seen. 9 subjects were also seen in the fifth year 
(1998), and a diagnosis of MGUS, typed as IgM lambda, was noted for 1 patient who did not 
have mention of the disease previously in her chart (initial SPEP 0.35 g/dL). During this year, 
the patient with lymphoma also developed acute monoblastic leukemia. Another subject I developed breast cancer (initial SPEP 0.44 g/dL). In the sixth year, 11 subjects were seen, one 
who developed multiple myeloma, as mentioned previously. Her SPEP level rose from an initial 
value of 1.25 g/dL to 2.96 g/dL by 1999. She was started on chemotherapy with melphalan and 
prednisone and was followed with monthly SPEPs. In 2000, 11 subjects were seen, with one 
beginning to have annual SPEP evaluations (initial SPEP 0.44 g/dL). In 2001, 13 subjects were 
seen, and one had an SPEP with a globulin level of 0.9 g/dL (initial SPEP 0.35 g/dL). UPEP was 
done on this patient without results noted in the chart. In the ninth year, 13 subjects were seen in 
the medical community, and 7 have been seen so far this year (2003). 
Table 4 lists the available health care utilization outcomes data and serum globulin level 
for each subject. From 1992 to present, the number of hospitalizations among the subjects 
ranged from 1 to 9, with a mean of 3.4. The subjects with the highest number of hospitalizations 
had initial SPEPs of 0.44, 1.04, and 1.06 g/dL, and the subjects with only 1 hospitalization 
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documented had initial SPEPs that ranged from 0.68 to 2.22 g/dL. The number of outpatient 
clinic visits ranged from 1 to 52, with a mean of 15. The patient with the highest number of 
outpatient visits had an initial SPEP of 0.52 g/dL, and the subjects with only 1 outpatient visit 
documented had initial SPEPs of 0.81 and 1.48 g/dL. The number of ER visits ranged from 1 to 
7, with a mean of 2.6. The subject with the highest number ofER visits had an initial SPEP of 
1.04 g/dL, and the subjects with only 1 ER visit documented had initial SPEPs that ranged from 
0.44 to 1.57 g/dL. 5 NH admissions were noted, in subjects with initial SPEPs of 0.94, 1.35, 
1.45, 1.8, and 2.49 g/dL. 
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Discussion 
MGUS is a plasma cell disorder that has significant potential to progress to more serious 
disease such as multiple myeloma. Because there are no factors other than M-protein level that 
can help predict progression of the disease, it is important for patients with MGUS to receive 
regular follow-up. In this study, we examined the health utilization patterns and follow-up care 
of MGUS patients. No previous studies have looked at these outcomes in MGUS patients. 
Our hypothesis that MGUS patients should experience higher health care utilization was 
not fully supported, since we found that having MGUS was not significantly associated with 
increased outpatient visits, hospitalizations, or ER visits. The MGUS subjects did have 
significantly more NH admissions than the non-MGUS subjects, but the number of outpatient 
visits is likely a stronger outcome variable than NH admissions for measuring adequate health 
utilization, because many more patients make an outpatient visit than become admitted to a 
nursing home. MGUS subjects were also found to have significantly fewer ER visits than non-
MGUS subjects. 
One explanation for why there were no significant differences in number of 
hospitalizations and outpatient visits between the subjects with MGUS and those without is that 
the general overall health in the two groups is similar. In a previous study (15), it was found that 
the presence of MGUS was not associated with specific comorbidities nor impaired functional 
status, and none of the health conditions surveyed, including cancer, cardiovascular disease, 
cerebrovascular disease, diabetes, hip fracture or other broken bones, or arthritis, showed any 
correlation with monoclonal garnrnopathy prevalence (all P>0.24). This suggests that general 
health and disease status does not differ significantly between those with and without MGUS. If 
the overall health and functional status is similar in those with MGUS and those without, then 
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there probably is no need for increased hospitalizations, or ER vists. However, it would still be 
expected that MGUS patients should have a greater number of outpatient visits in order to 
receive the recommended follow-up studies. 
Within the group of subjects with MGUS, the level of M-protein was found to be 
correlated with number of ER visits and hospitalizations, but not with outpatient visits or NH 
admissions. This may indicate that subjects with higher levels of M -protein develop more L 
serious disease than those with lower levels, requiring a higher rate of hospitalizations and ER 
visits for acute care rather than outpatient visits or NH admissions, which are better indicators for 
long-term follow-up care. Without a corresponding increase in outpatient visits, it cannot be 
concluded that patients with higher levels of M-protein are receiving more follow-up care for 
MGUS than those with lower levels of M-protein. 
Guidelines state that asymptomatic MGUS patients should receive, at minimum, annual 
SPEPs to follow M-protein levels (11). Furthermore, patients with higher M-protein levels 
require more studies and more frequent follow-up. If the recommendations were adequately 
followed, MGUS patients should have a higher number of outpatient visits compared to those 
without, and patients with higher M-protein levels should have more outpatient visits compared 
to those with lower levels. This was not the case in our study, which, along with the incomplete 
follow-up of MGUS found in the majority of medical records, may indicate that MGUS patients 
generally do not receive proper follow-up. 
Medical records of 37 patients from 1992 to 2003 revealed that, after initial diagnosis of 
MGUS, baseline studies were very inadequate, with only a small minority of patients receiving 
UPEPs, bloodwork including creatinine, calcium, hemoglobin, platelets, and white blood cells, 
and bone scans or skeletal surveys. Long-term follow-up of MGUS patients was also minimal, 
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with only 19% receiving repeat SPEPs. Although these results are derived only from a sample of 
the totall06 patients with MGUS, they may be representative of the general care of older MGUS 
patients. These results are concerning, because M-protein levels need to be followed to watch 
for development of serious plasma cell disorders. 
There are several possible explanations for the lack of follow-up in these MGUS patients. 
On the one hand, we may just have received incomplete medical records for the patients. 
Patients may not have listed all of their health care providers on the release of medical 
information consent forms, which would have resulted in our failing to request medical records 
from all of their sources of medical care. Also, we were unable to locate all medical records, so 
that records may have been obtained from primary care physicians but not hospitals, or vice 
versa. In addition, few nursing homes were able to provide medical records, so if a patient 
received the majority of their medical care in a nursing home, we had little documentation of 
that. Alternatively, it is possible that patients did receive follow-up, but the studies were not 
thoroughly documented in the medical records. Another explanation for the lack of follow-up is 
that some of the patients' health care providers may have been unaware of their patients' MGUS 
' [ 
status. Only 15 of the 37 patients with medical records available had specifically requested that 
M-protein results from the study in 1992 be sent to their primary care physicians, so we only 
know for snre that those providers were aware of their patient's MGUS diagnosis. However, it 
would be hoped that the other 22 patients might have mentioned the abnormal proteins to their 
physicians as well, initiating some labwork. 
On the other hand, the inadequate follow-up of the MGUS patients seen in onr study 
might indicate that the condition of MGUS is frequently deemed as unconcerning and eventually 
lost in follow-up. Since MGUS is regarded as a generally benign disease, other conditions take 
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precedence in the physician's "assessment and plan" list. Examining the medical charts in which 
the diagnosis of MGUS was noted, MGUS typically was listed prominently under the 
"assessment and plan" for the first few months following diagnosis, but gradually fell lower and 
lower on the list. With MGUS, patients are clinically asymptomatic, so they do not remind their 
physicians of their condition each time they come in for a check -up. They present with 
complaints of other ailments that do manifest symptomatically, and these ailments then become 
the primary concern of their health care providers. Gradually, if the physician does not vigilantly 
keep track of all the patient's health conditions, MGUS can disappear from the "assessment and 
plan" list altogether. Unfortunately, these patients still have considerable risk of developing 
mnltiple myeloma and other plasma cell disorders (6). 
Ageism is another factor that may play a role in reducing follow-up care of older MGUS 
patients. The workup of MGUS, with the potential need for radiological evaluation and bone 
marrow biopsy, may not be deemed as important or may even be considered a bother to older 
subjects. Ageism has been found to affect many aspects of medical care, from diagnosis and 
monitoring to treatment. It was found in a study of 15,299 patients with colorectal cancer that 
increasing age was associated with markedly decreased rates of histological verification of the 
cancer, surgery, and chemotherapy (16). 
It is important to emphasize to both patients and physicians the importance of following 
up MGUS. Regarding patients, health care utilization patterns have been found to be strongly 
associated with a patient's perception of his or her own need for medical care. In a study looking 
at determinants of health care access and use, 4,162 residents of North Carolina were surveyed, 
and it was found that self-perceived need for care (self-rated health status) was the highest 
predictor for health services use (12). Other factors like gender, education, marital status, and 
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age all had much weaker effects on health care utilization. Therefore, physicians should take 
time to help their MGUS patients comprehend the potential for progression to more serious 
disease and the necessity for follow-up in order to establish a self-perceived need for care. 
Physicians themselves should follow an MGUS patient with similar vigilance as for a 
patient with any other pre-malignant condition. Screening for MGUS and its possible 
progression to multiple myeloma is comparable to other forms of cancer screening. Just as a 
patient with adenomatous polyps would receive more frequent colonoscopies to watch for 
development of colon cancer, a patient with MGUS should receive annual SPEPs to watch for 
development of multiple myeloma (17). Screening is appropriate for diseases that are common, 
have a detectable presymptomatic phase during which treatment can benefit the patient more 
than treatment after symptoms occur, and when benefits of testing and early treatment outweigh 
the harms. A screening test also needs to be simple, sensitive and specific, reliable, low in cost, 
as convenient and painless as possible, and not cause morbidity (18,19). Serial SPEPs are a 
reasonable screening test in those with MGUS to watch for development of multiple myeloma. 
In elderly patients, myeloma is relatively common, and it is detectable in its presymptomatic 
phase as MGUS. SPEP requires a blood-draw from a patient, which can be done when blood is 
collected for other routine labwork, reducing its cost. It is also high! y sensitive and specific in 
identifying abnormalities consistent with monoclonal gammopathies. In a study of 1,518 
patients, agarose gel electrophoresis had a sensitivity and specificity of 91% and 99%, 
respectively (20). If an M-protein is discovered and becomes progressively higher in follow-up, 
surpassing the threshhold for diagnosis of multiple myeloma, treatment can be initiated before 
symptoms occur, potentially lengthening survival and improving quality of life. 
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As with other cancer screening, the presence of other comorbidities should not 
discourage follow-up of MGUS as screening for multiple myeloma. Even though other 
comorbidities may seem to warrant more attention and have more immediate impact on quality 
of life due to clinically apparent symptoms, cancer screening should not be neglected. 
Auspiciously, in one study of 2,225 elderly members, subjects with high numbers of 
comorbidities were generally not found to receive significantly less cancer screening than those 
with fewer comorbidities (21). The types of cancer screening analyzed in that study included 
clinical breast examination, mammography, Papanicolaou smear, and fecal occult blood testing. 
One would hope that follow-up of MGUS in the form of annual SPEPs would not be 
overshadowed by other comorbidities as well. 
Lastly, follow-up of MGUS patients may be inadequate because physicians and patients 
are unaware of the guidelines for clinical practice standards regarding screening and monitoring 
of patients with MGUS. The guidelines were published in 1999 in a medical journal, but they 
have not been disseminated to the public or professionals beyond. These were also the only 
guidelines that have been published regarding the follow-up care of a patient with MGUS. An 
update of these guidelines to an increased audience may prove useful in improving the follow-up 
care of an MGUS patient. 
The results of this study suggest a need to increase awareness among patients and 
physicians of existing guidelines for follow-up care of an MGUS patient and the significant 
potential for MGUS to develop into more clinically significant disease or malignancy. 
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Figure 1. Distribution of M-protein level among subjects with MGUS 
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Table 1. Comparison of MGUS vs. non-MGUS Snbjects on Demographic, Behavioral, 
and Comorbidity Factors. EPESE, 1992 
Variable Mean or Percent with Variable p-valne 
MGUS(106) non-MGUS (1624) 
Age (yrs) 79.1 77.8 0.02 
Education (yrs) 8.3 9.1 0.06 
Pack-years smoking 17.6 15.1 0.37 
Alcohol consumption (#drinks/month) 2.6 4.2 0.25 
Sex (Female) 55.7 65.7 0.04 
Race (African-American) 72.6 51.7 <0.0001 
Married 38.7 36.1 0.6 
Employed 13.2 9.5 0.24 
Comorbidities 
Coronary artery disease 20.8 21.9 0.9 
Hypertension 74.5 69.6 0.33 
Cerebrovascular disease 11.3 11.8 1 
Cancer 14.2 14.8 1 
Diabetes 28.3 23.3 0.24 
Broken hip 4.7 4.7 1 
Broken bones 23.6 30 0.19 
Arthritis 72.6 72.8 1 
Osteoporosis 1.9 6.9 0.04 
Glaucoma 10.4 10.4 1 
Parkinson's disease 1.9 1.5 0.68 
Anemia 4.7 4.5 0.81 
Lung disease 15.1 11.8 0.35 
Liver disease 0.9 0.3 0.32 
Depression 9.4 8.4 0.72 
Cognitive Impairment 12.3 12.4 1 
L 
Table 2. Beta Estimates and Odds Ratios for the Association Between MGUS Diagnosis 
and Health Care Utlilization. EPESE, 1992 
Beta OR p-value 
MGUS and: 
Number of hospitalizations 0.16 1.17 0.53 
Number ofER visits -0.27 0.76 0.04 
Number of NH admissions 0.29 1.34 0.04 
Number of outpatient visits -1.81 0.16 0.08 
(non-MGUS subjects is control group) 
Table 3. Correlations Between M-Protein Level and Health Care Utlilization. EPESE, 1992 
Pearson's correlation p-value 
coefficient ( r) 
M -protein level and: 
Number of hospitalizations 0.6 0.02 
Number of ER visits 0.48 <0.0001 
Number of NH admissions 0.37 0.42 
Number of outpatient visits 0.17 0.17 
j 
= ~----
Table 4. Serum Globulin Level and Health Utilization Among Subjects 
with MGUS 1992-present 
Globulin Hospitalizations Outpatient ER Visits Nursing Home 
Level Visits Admissions 
0.31 2 
0.35 2 13 4 
0.44 9 20 1 
0.52 4 52 
0.67 5 28 1 
0.68 1 
0.69 
0.71 7 31 
0.72 
0.73 4 
0.8 4 2 
0.81 1 
0.86 3 30 
0.94 7 21 
1 1 
1.01 3 
1.04 4 11 2 
1.04 9 32 7 
1.06 9 20 1 
1.07 2 
1.11 1 2 
1.12 2 
1.21 1 2 
1.25 4 33 4 
1.32 1 2 3 
1.35 2 16 
1.45 3 16 
1.48 1 
1.57 1 2 1 
1.8 2 
1.82 3 
1.93 2 
2.22 1 11 
2.49 3 7 
3.07 
4.18 2 
1 
1 
1 
1 
1 
r 
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